Is L-Carnitine Supplementation Cognitive Performance Randomized Trial safe?

The current Migaku evidence database contains 2 reusable source documents for L-Carnitine Supplementation Cognitive Performance Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - 1 Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults (). [Wang Xiaolan (2026); evidence level 3] - 1 2 3 4 5 By the age of 70, individuals may experience a 25%−30% reduction in muscle mass, which is strongly associated with impaired mobility, falls, and loss of independence (). [Wang Xiaolan (2026); evidence level 3] - Low circulating glycine levels have been associated with insulin resistance, obesity, and higher cardiometabolic risk (,). [Wang Xiaolan (2026); evidence level 3] - In this review, the term “older adults” generally refers to individuals aged ≥60 or ≥65 years, consistent with definitions used by the World Health Organization and most geriatric clinical trials. [Wang Xiaolan (2026); evidence level 3] - This narrative review evaluates Meldonium's biochemical mechanisms, pharmacokinetics, safety profile, and the quality of evidence surrounding its use in athletes. [Malm C (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.